FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Epirubicin Hydrochloride Injection
Status: Discontinuation
»Therapeutic Categories: Oncology

Expand all

Hospira, Inc. (New 06/09/2017)

Company Contact Information:
844-646-4398

Presentation Posting Date Related Information
Epirubicin Hydrochloride Injection 200 mg/100 mL (2 mg/mL) Single Dose ONCO-TAIN Glass Fliptop Vial (NDC 61703-0359-59) 06/09/2017 Discontinuation of the manufacture of the drug.
Epirubicin Hydrochloride Injection 50 mg/25 mL (2 mg/mL) Single Dose ONCO-TAIN™ Glass Fliptop Vial (NDC 61703-0359-93) 06/09/2017 Discontinuation of the manufacture of the drug.

Impax Laboratories (New 08/25/2017)

Company Contact Information:
877-994-6729

Presentation Posting Date Related Information
50 mg/25 mL single-dose vial (NDC 0115-1675-72) 08/25/2017 A business decision was made to discontinue manufacture of the drug product. This product discontinuation is not related to product quality, safety, or efficacy. The anticipated final date for marketing is December 2017.
200 mg/100 mL single-dose vial (NDC 0115-1675-73 08/25/2017 A business decision was made to discontinue manufacture of the drug product. This product discontinuation is not related to product quality, safety, or efficacy. The anticipated final date for marketing is December 2017.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English